SCHEMBL18353487

SCHEMBL18353487

Cc1cc(Cl)ccc1CNc1nc[nH]n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.55
HDAC6 Q9UBN7 2/20 0.55
HDAC3 O15379 1/20 0.55
HDAC2 Q92769 1/20 0.55
P2RX7 Q99572 4/20 0.41
PPARG P37231 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
NR2E3 Q9Y5X4 1/20 0.40
NCOR2 Q9Y618 1/20 0.40
JAK3 P52333 1/20 0.39
HPGD P15428 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16995668 0.85 MAPT (0.49) HDAC1HDAC6P2RX7HPGDNPSR1
SCHEMBL18353624 0.78 ABL1 (0.47) P2RX7PPARGRXFP1NR2E3NCOR2
SCHEMBL18353625 0.76 STAT3 (0.54) NPSR1SMN1; SMN2ALDH1A1
SCHEMBL16995685 0.72 HDAC3 (0.51) HDAC1HDAC6HDAC3HDAC2SMN1; SMN2
SCHEMBL4730174 0.71 HDAC1 (1.00) HDAC1HDAC6HDAC3HDAC2HDAC8
SCHEMBL16995674 0.71 SMN1; SMN2 (0.58) NPSR1SMN1; SMN2CYP1A2CYP3A4CYP2D6
SCHEMBL18353997 0.71 ABL1 (0.51) HDAC1HDAC6HDAC3HDAC2P2RX7
SCHEMBL30435034 0.70 SLC6A4 (0.57) HDAC1HDAC6HDAC3HDAC2SLC6A2
SCHEMBL8279448 0.70 SLC6A4 (0.57) HDAC1HDAC6HDAC3HDAC2SLC6A2
SCHEMBL16995662 0.70 FNTA (0.65) NPSR1SMN1; SMN2CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170001968-A1 AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2017-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170001968-A1 AMINOTRIAZOLE- AND AMINOTETRAZOLE-BASED KDM1A INHIBITORS AS EPIGENETIC MODULATORS KDM1A, KDM1B, KDM3A HDAC1 60/4885HDAC6 354/4885HDAC3 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.